Genotype 4 hepatitis C virus-a review of a diverse genotype

2017 World Health Organization, 2022 Alter, 1999, Discovery of non-A, non-B hepatitis and identification of its etiology, Am J Med, 107, 16, 10.1016/S0002-9343(99)00375-7 Houghton, 2009, Discovery of the hepatitis C virus, Liver Int, 29, 82, 10.1111/j.1478-3231.2008.01925.x Westbrook, 2014, Natural history of hepatitis C, J Hepatol, 61, S58, 10.1016/j.jhep.2014.07.012 Messina, 2015, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, 61, 77, 10.1002/hep.27259 Flisiak, 2016, Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study, Clin Exp Hepatol, 4, 138, 10.5114/ceh.2016.63870 Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial, Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 Moreno, 2015, Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4, J Hepatol, 62, 1047, 10.1016/j.jhep.2014.12.031 Hézode, 2016, Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4), Antivir Ther, 21, 195, 10.3851/IMP2985 Bhatia, 2014, Sofosbuvir: a novel treatment option for chronic hepatitis C infection, J Pharmacol Pharmacother, 5, 278, 10.4103/0976-500X.142464 Flisiak, 2021, Five-year follow-up of cured HCV patients under real-world interferon-free therapy, Cancers, 13, 3694, 10.3390/cancers13153694 Roulot, 2007, Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection, J Viral Hepat, 14, 460, 10.1111/j.1365-2893.2006.00823.x Gupta, 2019, Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial, Lancet Gastroenterol Hepatol., 4, 119, 10.1016/S2468-1253(18)30382-0 Kamal, 2008, Hepatitis C genotype 4: what we know and what we don't yet know, Hepatology, 47, 1371, 10.1002/hep.22127 Pybus, 2003, The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach, Mol Biol Evol, 20, 381, 10.1093/molbev/msg043 Alberti, 2016, Literature review of the distribution of hepatitis C virus genotypes across Europe, J Med Virol, 88, 2157, 10.1002/jmv.24573 Fernández-Arcás, 2006, High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses, J Med Virol, 78, 1429, 10.1002/jmv.20706 Franco, 2007, Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1, Virus Res, 123, 161, 10.1016/j.virusres.2006.09.001 de Bruijne, 2009, Emergence of Hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles, J Clin Microbiol, 47, 3832, 10.1128/JCM.01146-09 Chlabicz, 2008, High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in North-Eastern Poland, J Med Virol, 80, 615, 10.1002/jmv.21107 Panasiuk, 2013, Distribution of HCV genotypes in Poland, Przegl Epidemiol, 67, 99 Flisiak, 2016, Prevalence of HCV genotypes in Poland – the EpiTer study, Clin Exp Hepatol, 4, 144, 10.5114/ceh.2016.63871 Smith, 2014, Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource, Hepatology, 59, 318, 10.1002/hep.26744 Nicot, 2005, Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France, J Gen Virol, 86, 107, 10.1099/vir.0.80409-0 Leandro, 2006, Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data, Gastroenterology, 130, 1636, 10.1053/j.gastro.2006.03.014 Kamal, 2006, Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis, Hepatology, 43, 771, 10.1002/hep.21117 Besheer, 2017, Prediction of fibrosis progression rate in patients with chronic hepatitis C genotype 4: role of cirrhosis risk score and host factors, J Interferon Cytokine Res, 37, 97, 10.1089/jir.2016.0111 Mohsen, 2003, Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients, Gut, 52, 1035, 10.1136/gut.52.7.1035 Zarębska-Michaluk, 2022, Pangenotypic and genotype-specific antivirals in the treatment of HCV genotype 4 infected patients with HCV monoinfection and HIV/HCV coinfection, J Clin Med, 11, 389 Tsochatzis, 2007, Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors, Am J Gastroenterol, 102, 634, 10.1111/j.1572-0241.2006.01025.x Khattab, 2010, Hepatic steatosis in genotype 4 chronic hepatitis C patients, J Clin Gastroenterol, 10.1097/MCG.0b013e3181d2ef1a Rubbia-Brandt, 2000, Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3, J Hepatol, 33, 106, 10.1016/S0168-8278(00)80166-X Ibrahim, 2014, Cancer incidence in Egypt: results of the national population-based cancer registry program, J Cancer Epidemiol, 2014, 1, 10.1155/2014/437971 Rashed, 2020, Hepatocellular Carcinoma (HCC) in Egypt: a comprehensive overview, J Egypt Natl Cancer Inst, 32 Abdel-Hamid, 2007, Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma, J Gen Virol, 88, 1526, 10.1099/vir.0.82626-0 Abdo, 2004, Management of hepatitis C virus genotype 4, J Gastroenterol Hepatol, 19, 1233, 10.1111/j.1440-1746.2003.03325.x Fried, 2002, Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, 975, 10.1056/NEJMoa020047 Marcellin, 2012, High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials, Hepatology, 56, 2039, 10.1002/hep.25892 Kozielewicz, 2018, Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4, Przeglad Gastroenterol, 13, 22 Khattab, 2010, Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients, Am J Gastroenterol, 105, 10.1038/ajg.2010.110 El Raziky, 2013, The effect of peginterferon alpha-2a vs. Peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study, Hepat Mon, 13, 10.5812/hepatmon.10069 Kamal, 2007, Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response, Hepatology, 46, 1732, 10.1002/hep.21917 Ferenci, 2008, Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response, Gastroenterology, 135, 451, 10.1053/j.gastro.2008.04.015 Ferenci, 2010, Peginterferon Alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response, Gastroenterology, 138, 503, 10.1053/j.gastro.2009.10.058 Jacobson, 2016, Daclatasvirvstelaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1, World J Gastroenterol, 22, 3418, 10.3748/wjg.v22.i12.3418 Jensen, 2015, Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders, J Hepatol, 63, 30, 10.1016/j.jhep.2015.02.018 Lawitz, 2013, Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, 1878, 10.1056/NEJMoa1214853 Elsharkawy, 2017, Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt, Aliment Pharmacol Ther, 45, 681, 10.1111/apt.13923 Ruane, 2015, Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, J Hepatol, 62, 1040, 10.1016/j.jhep.2014.10.044 Shiha, 2019, Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt, Gut, 68, 721, 10.1136/gutjnl-2017-315906 Ioannou, 2016, Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system, Gastroenterology, 151, 457, 10.1053/j.gastro.2016.05.049 Crespo, 2017, Real-world effectiveness and safety of oral combination antiviral therapy for hepatitis C virus genotype 4 infection, Clin Gastroenterol Hepatol, 15, 945, 10.1016/j.cgh.2017.02.020 Gupta, 2019, Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial, Lancet Gastroenterol Hepatol., 4, 119, 10.1016/S2468-1253(18)30382-0 Asselah, 2016, Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial, Lancet Gastroenterol Hepatol., 1, 25, 10.1016/S2468-1253(16)30001-2 Waked, 2016, Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial, Lancet Gastroenterol Hepatol., 1, 36, 10.1016/S2468-1253(16)30002-4 Asselah, 2018, Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis, Liver Int, 38, 1583, 10.1111/liv.13727 Halota, 2020, Recommendations of the polish group of experts for HCV for the treatment of hepatitis C in 2020, Clin Exp Hepatol, 6, 163, 10.5114/ceh.2020.98606 Asselah, 2018, Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis, Clin Gastroenterol Hepatol, 16, 417, 10.1016/j.cgh.2017.09.027 Forns, 2017, Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial, Lancet Infect Dis, 17, 1062, 10.1016/S1473-3099(17)30496-6 Brown, 2020, Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial, J Hepatol, 72, 441, 10.1016/j.jhep.2019.10.020 Gane, 2017, Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment, N Engl J Med, 377, 1448, 10.1056/NEJMoa1704053 Lampertico, 2020, Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis, J Hepatol, 72, 1112, 10.1016/j.jhep.2020.01.025 Curry, 2015, Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis, N Engl J Med, 373, 2618, 10.1056/NEJMoa1512614 Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 Mangia, 2020, Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts, Liver Int, 40, 1841, 10.1111/liv.14537 Bourlière, 2017, Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection, N Engl J Med, 376, 2134, 10.1056/NEJMoa1613512 Yeo, 2022, The impact of COVID-19 on the cascade of care of HCV in the US and China, Ann Hepatol, 27, 10.1016/j.aohep.2022.100685 Hill, 2017, The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries, J Virus Erad, 3, 117, 10.1016/S2055-6640(20)30329-0 Davis, 2019, Highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments, Hepatology, 69, 1426, 10.1002/hep.30342 2018, European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018, J Hepatol, 69, 461, 10.1016/j.jhep.2018.03.026 Ghany, 2020, Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection, Hepatology, 71, 686, 10.1002/hep.31060 Fourati, 2019, Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r, Hepatology, 69, 513, 10.1002/hep.30225 Abergel, 2016, Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection, Hepatology, 64, 1049, 10.1002/hep.28706 Pawlotsky, 2016, Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, Gastroenterology, 151, 70, 10.1053/j.gastro.2016.04.003 Sarrazin, 2021, Treatment failure with DAA therapy: importance of resistance, J Hepatol, 74, 1472, 10.1016/j.jhep.2021.03.004 Dietz, 2020, Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection, J Viral Hepat, 27, 974, 10.1111/jvh.13322 Sonderup, 2017, Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030, Lancet Gastroenterol Hepatol., 2, 910, 10.1016/S2468-1253(17)30249-2 El-Akel, 2017, National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care, J Viral Hepat, 24, 262, 10.1111/jvh.12668 http://www.hepbcppa.org/wp-content/uploads/2012/08/Esmat-A-nation-prog-for- (accessed May 29, 2022). Omran, 2018, Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations, World J Gastroenterol, 24, 4330, 10.3748/wjg.v24.i38.4330 Plan of action for the prevention n.d. http://www.emro.who.int/images/stories/egypt/VH_Plan_of_Action_FINAL_PRINT1.pdf (accessed May 29, 2022). Hassanin, 2021, Egypt's ambitious strategy to eliminate hepatitis C virus: a case study, Glob Health Sci Pract, 9, 187, 10.9745/GHSP-D-20-00234 https://www.wipo.int/edocs/pubdocs/en/wipo_pub_gii_2019-chapter12.pdf (accessed May 29, 2022). 2020 Waked, 2020, Screening and treatment program to eliminate hepatitis C in Egypt, N Engl J Med, 382, 1166, 10.1056/NEJMsr1912628